

# Rosemary Wyber

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9050563/publications.pdf>

Version: 2024-02-01

45  
papers

1,479  
citations

567281

15  
h-index

330143

37  
g-index

47  
all docs

47  
docs citations

47  
times ranked

1564  
citing authors

#	ARTICLE	IF	CITATIONS
1	Improving primary prevention of acute rheumatic fever in Australia: consensus primary care priorities identified through an eDelphi process. <i>BMJ Open</i> , 2022, 12, e056239.	1.9	2
2	Awareness, Education, and Advocacy. , 2021, , 289-300.		0
3	Structured review of primary interventions to reduce group A streptococcal infections, acute rheumatic fever and rheumatic heart disease. <i>Journal of Paediatrics and Child Health</i> , 2021, 57, 797-802.	0.8	10
4	Primary prevention of acute rheumatic fever. <i>Australian Journal of General Practice</i> , 2021, 50, 265-269.	0.8	4
5	Formative evaluation of a community-based approach to reduce the incidence of Strep A infections and acute rheumatic fever. <i>Australian and New Zealand Journal of Public Health</i> , 2021, 45, 449-454.	1.8	8
6	Rheumatic heart disease in Indigenous young peoples. <i>The Lancet Child and Adolescent Health</i> , 2021, 5, 437-446.	5.6	17
7	Improving the well-being for young people living with rheumatic heart disease: A peer support pilot program through Danila Dilba Health Service. <i>Health Promotion Journal of Australia</i> , 2021, , .	1.2	1
8	Protocol for the systematic review of the epidemiology of superficial Streptococcal A infections (skin and throat) in Australia. <i>PLoS ONE</i> , 2021, 16, e0255789.	2.5	1
9	A community-based program to reduce acute rheumatic fever and rheumatic heart disease in northern Australia. <i>BMC Health Services Research</i> , 2021, 21, 1127.	2.2	8
10	Ending rheumatic heart disease in Australia: the evidence for a new approach. <i>Medical Journal of Australia</i> , 2020, 213, S3-S31.	1.7	25
11	Respiratory clinics and rural and Aboriginal health. <i>British Journal of General Practice</i> , 2020, 70, 435-435.	1.4	1
12	Subcutaneous administration of benzathine benzylpenicillin G has favourable pharmacokinetic characteristics for the prevention of rheumatic heart disease compared with intramuscular injection: a randomized, crossover, population pharmacokinetic study in healthy adult volunteers. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 2951-2959.	3.0	14
13	The American Heart Association's Call to Action for Reducing the Global Burden of Rheumatic Heart Disease: A Policy Statement From the American Heart Association. <i>Circulation</i> , 2020, 142, e358-e368.	1.6	30
14	Contemporary Incidence and Prevalence of Rheumatic Fever and Rheumatic Heart Disease in Australia Using Linked Data: The Case for Policy Change. <i>Journal of the American Heart Association</i> , 2020, 9, e016851.	3.7	67
15	Quality of benzathine penicillin G: A multinational cross-sectional study. <i>Pharmacology Research and Perspectives</i> , 2020, 8, e00668.	2.4	5
16	Voices behind the Statistics: A Systematic Literature Review of the Lived Experience of Rheumatic Heart Disease. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 1347.	2.6	25
17	Rheumatic Heart Disease: Tools for Implementing Programmes. <i>Global Heart</i> , 2020, 10, 79.	2.3	4
18	Benzathine Penicillin G for the Management of RHD: Concerns About Quality and Access, and Opportunities for Intervention and Improvement. <i>Global Heart</i> , 2020, 8, 227.	2.3	48

#	ARTICLE	IF	CITATIONS
19	Public health and economic perspectives on acute rheumatic fever and rheumatic heart disease. Medical Journal of Australia, 2019, 211, 250.	1.7	15
20	Severe adverse events following benzathine penicillin G injection for rheumatic heart disease prophylaxis: cardiac compromise more likely than anaphylaxis. Heart Asia, 2019, 11, e011191.	1.1	16
21	Call for a national sore throat guideline. Medical Journal of Australia, 2019, 210, 477.	1.7	5
22	NCDs and the WHO Essential Medicines Lists: children need universal health coverage too. The Lancet Child and Adolescent Health, 2019, 3, 756-757.	5.6	3
23	&lt;p&gt;The End Rheumatic Heart Disease in Australia Study of Epidemiology (ERASE) Project: data sources, case ascertainment and cohort profile&lt;/p&gt;. Clinical Epidemiology, 2019, Volume 11, 997-1010.	3.0	24
24	Availability and administration of benzathine penicillin G for the prevention of rheumatic fever in Africa: report of the Working Group on Penicillin, Pan-African Society of Cardiology Task Force on Rheumatic Heart Disease. Cardiovascular Journal of Africa, 2019, 30, 369-372.	0.4	1
25	Lessons learned in the development of sustained release penicillin drug delivery systems for the prophylactic treatment of rheumatic heart disease (RHD). Drug Delivery and Translational Research, 2018, 8, 729-739.	5.8	11
26	Rheumatic Heart Disease Worldwide. Journal of the American College of Cardiology, 2018, 72, 1397-1416.	2.8	137
27	The rationale for action to end new cases of rheumatic heart disease in Australia. Medical Journal of Australia, 2017, 207, 322-323.	1.7	9
28	Rheumatic heart disease: infectious disease origin, chronic care approach. BMC Health Services Research, 2017, 17, 793.	2.2	37
29	The WHF Roadmap for Reducing CV Morbidity and Mortality Through Prevention and Control of RHD. Global Heart, 2017, 12, 47.	2.3	44
30	A Comprehensive Needs Assessment Tool for Planning RHD Control Programs in Limited Resource Settings. Global Heart, 2017, 12, 25.	2.3	13
31	Preliminary consultation on preferred product characteristics of benzathine penicillin G for secondary prophylaxis of rheumatic fever. Drug Delivery and Translational Research, 2016, 6, 572-578.	5.8	24
32	Acute rheumatic fever and rheumatic heart disease. Nature Reviews Disease Primers, 2016, 2, 15084.	30.5	371
33	Myositis complicating benzathine penicillin-G injection in a case of rheumatic heart disease. IDCases, 2016, 4, 6-7.	0.9	5
34	Treating trade: the case for clinical engagement with regional trade agreements. Lancet Diabetes and Endocrinology, the, 2015, 3, 400-402.	11.4	1
35	Big data in global health: improving health in low- and middle-income countries. Bulletin of the World Health Organization, 2015, 93, 203-208.	3.3	187
36	Evolution, evidence and effect of secondary prophylaxis against rheumatic fever. Journal of the Practice of Cardiovascular Sciences, 2015, 1, 9.	0.1	7

#	ARTICLE	IF	CITATIONS
37	Making mapping matter: a case study for short project international partnerships by global public health students. <i>Global Health Action</i> , 2014, 7, 23593.	1.9	3
38	The case for global investment in rheumatic heart-disease control. <i>Bulletin of the World Health Organization</i> , 2014, 92, 768-770.	3.3	26
39	Position statement of the World Heart Federation on the prevention and control of rheumatic heart disease. <i>Nature Reviews Cardiology</i> , 2013, 10, 284-292.	13.7	224
40	The Gr8est Good: Use of text messages between doctors in a tertiary hospital. <i>Journal of Communication in Healthcare</i> , 2013, 6, 29-34.	1.5	4
41	A Conceptual Framework for Comprehensive Rheumatic Heart Disease Control Programs. <i>Global Heart</i> , 2013, 8, 241.	2.3	13
42	The Second Rheumatic Heart Disease Forum Report. <i>Global Heart</i> , 2013, 8, 253.	2.3	11
43	Prevention of Rheumatic Fever and Heart Disease: Nepalese Experience. <i>Global Heart</i> , 2013, 8, 247.	2.3	13
44	Relationships between medical students and drug companies in New Zealand. <i>New Zealand Medical Journal</i> , 2011, 124, 58-64.	0.5	2
45	Medical students at the 18th IPPNW World Congress in Delhi. <i>Medicine, Conflict and Survival</i> , 2008, 24, 236-241.	0.9	0